United Therapeutics Corporation (NASDAQ:UTHR) Director Richard Giltner Sells 3,036 Shares

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) Director Richard Giltner sold 3,036 shares of the stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $289.60, for a total value of $879,225.60. Following the completion of the transaction, the director now owns 19,384 shares in the company, valued at $5,613,606.40. This represents a 13.54% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

United Therapeutics Trading Down 0.7%

NASDAQ:UTHR traded down $1.88 during trading hours on Thursday, hitting $284.09. 364,679 shares of the company traded hands, compared to its average volume of 448,643. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $417.82. The firm has a 50-day moving average of $301.15 and a 200 day moving average of $326.23. The stock has a market capitalization of $12.82 billion, a price-to-earnings ratio of 11.34, a P/E/G ratio of 6.35 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. The business had revenue of $794.40 million during the quarter, compared to analyst estimates of $726.82 million. During the same quarter in the prior year, the business earned $6.17 earnings per share. The firm's revenue for the quarter was up 17.2% on a year-over-year basis. Equities research analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Hedge Funds Weigh In On United Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Dunhill Financial LLC increased its position in shares of United Therapeutics by 100.0% during the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock valued at $35,000 after purchasing an additional 50 shares during the period. SVB Wealth LLC bought a new position in United Therapeutics in the first quarter worth $32,000. Geneos Wealth Management Inc. boosted its stake in United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock worth $45,000 after buying an additional 85 shares in the last quarter. Sound Income Strategies LLC bought a new stake in United Therapeutics in the 1st quarter valued at $49,000. Finally, State of Wyoming bought a new stake in United Therapeutics in the 4th quarter valued at $62,000. Institutional investors and hedge funds own 94.08% of the company's stock.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. HC Wainwright restated a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a report on Monday, May 5th. Cantor Fitzgerald assumed coverage on United Therapeutics in a report on Monday, June 2nd. They set an "overweight" rating and a $405.00 price objective on the stock. Wells Fargo & Company restated an "equal weight" rating and issued a $314.00 target price (down from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. Morgan Stanley upped their target price on United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a research report on Thursday, May 1st. Finally, Bank of America lowered their price target on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a report on Wednesday, June 11th. Four equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, United Therapeutics has an average rating of "Moderate Buy" and an average price target of $393.08.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.